{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:16:09Z","timestamp":1776453369327,"version":"3.51.2"},"reference-count":46,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The standard induction treatment for acute myeloid leukemia (AML) has limited efficacy for patients with non\u2013low-risk AML. We conducted a multicenter study phase 1b\/2, Gruppo Italiano Malattie EMatologiche dell'Adulto AML1718, to investigate the safety and efficacy of venetoclax (VEN) combined with fludarabine, cytarabine, and idarubicin (V-FLAI) as an induction therapy for patients with non\u2013low-risk AML aged &amp;lt;65 years and at intermediate or high European LeukemiaNet risk. After a safety run-in, patients were randomly allocated to VEN 400 mg or VEN 600 mg cohorts. The primary objectives were safety and composite complete remission (bone marrow blasts of &amp;lt;5% with any recovery). We report a predefined interim analysis after 57 patients. Median exposure to VEN during induction was 22 days. Effectiveness and safety were similar between VEN 400 mg and VEN 600 mg cohorts. The 60-day mortality rate was 5.8%. Prolonged aplasia was observed in patients receiving high doses of cytarabine during consolidation. Composite CR was achieved in 84% of patients. With a median follow-up of 20.6 months, 1-year overall survival was 71%, 1-year disease-free survival was 66.2%, and 1-year cumulative incidence of relapse was 24%. V-FLAI is an effective induction therapy for young and fit patients. Fifty-five more patients will be enrolled in part 2; they will receive VEN 400 mg + FLAI as predefined and will be evaluated centrally for measurable residual disease. This trial was registered at www.clinicaltrials.gov as #NCT03455504.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014901","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T22:13:16Z","timestamp":1741299196000},"page":"2542-2552","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non\u2013low-risk AML"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-0515","authenticated-orcid":false,"given":"Giovanni","family":"Marconi","sequence":"first","affiliation":[{"name":"1Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universit\u00e0 di Bologna, Azienda Unit\u00e0 Sanitaria Locale della Romagna, Ospedale Santa Maria delle Croci, Ravenna, Italy"},{"name":"2Istituto di Ricovero e Cura a Carattere Scientifico Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori,\u201d Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8648-885X","authenticated-orcid":false,"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[{"name":"3Fondazione Gruppo Italiano Malattie EMatologiche dell'Adulto, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesta","family":"Audisio","sequence":"additional","affiliation":[{"name":"4Struttura Complessa Ematologia, Azienda Ospedaliera-Universitari Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-8333","authenticated-orcid":false,"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[{"name":"5Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1666-3100","authenticated-orcid":false,"given":"Marco","family":"Cerrano","sequence":"additional","affiliation":[{"name":"4Struttura Complessa Ematologia, Azienda Ospedaliera-Universitari Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Minotti","sequence":"additional","affiliation":[{"name":"6Unit\u00e0 Operativa Compless Ematologia, Azienda Ospedaliera-Universitari Policlinico Umberto I, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Paoloni","sequence":"additional","affiliation":[{"name":"3Fondazione Gruppo Italiano Malattie EMatologiche dell'Adulto, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-6078","authenticated-orcid":false,"given":"Fabio","family":"Guolo","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Clinic of Hematology, University of Genoa, Genoa, Italy"},{"name":"8Istituto di Ricovero e Cura a Carattere Scientifico San Martino Hospital, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-3913","authenticated-orcid":false,"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[{"name":"9Azienda Ospedaliero-Universitaria Senese, Universita\u2019 di Siena, Unit\u00e0 Operativa Compless Ematologia, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-5554","authenticated-orcid":false,"given":"Michela","family":"Rondoni","sequence":"additional","affiliation":[{"name":"10Azienda Unit\u00e0 Sanitaria Locale della Romagna, Ospedale Santa Maria delle Croci, Ravenna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albana","family":"Lico","sequence":"additional","affiliation":[{"name":"11Unit\u00e0 Operativa di Ematologia, Azienda Unit\u00e0 Locale Socio-Sanitaria 8 Berica, Ospedale di Vicenza, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-4839","authenticated-orcid":false,"given":"Matteo G.","family":"Carrabba","sequence":"additional","affiliation":[{"name":"12Istituto di Ricovero e Cura a Carattere Scientifico Ospedale S. Raffaele, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6915-5970","authenticated-orcid":false,"given":"Matteo Giovanni","family":"Della Porta","sequence":"additional","affiliation":[{"name":"13Department of Biomedical Sciences, Humanitas University, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2493-7749","authenticated-orcid":false,"given":"Marco","family":"Frigeni","sequence":"additional","affiliation":[{"name":"14Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Giaccone","sequence":"additional","affiliation":[{"name":"15Allogeneic Transplant and Cell Therapies Unit, Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Azienda Ospedaliera-Universitari Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germana","family":"Beltrami","sequence":"additional","affiliation":[{"name":"16Ematologia e Terapie Cellulari, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-3237","authenticated-orcid":false,"given":"Chiara","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"17Azienda Socio-Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Di Chio","sequence":"additional","affiliation":[{"name":"18Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Serio","sequence":"additional","affiliation":[{"name":"19Azienda Ospedaliera-Universitari San Giovanni di Dio e Ruggi D\u2019Aragona Salerno, Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Crea","sequence":"additional","affiliation":[{"name":"3Fondazione Gruppo Italiano Malattie EMatologiche dell'Adulto, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6003-3328","authenticated-orcid":false,"given":"Roberto","family":"Freilone","sequence":"additional","affiliation":[{"name":"4Struttura Complessa Ematologia, Azienda Ospedaliera-Universitari Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saveria","family":"Capria","sequence":"additional","affiliation":[{"name":"6Unit\u00e0 Operativa Compless Ematologia, Azienda Ospedaliera-Universitari Policlinico Umberto I, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-6049","authenticated-orcid":false,"given":"Antonio","family":"Curti","sequence":"additional","affiliation":[{"name":"5Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Minetto","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Clinic of Hematology, University of Genoa, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-3973","authenticated-orcid":false,"given":"Edoardo","family":"la Sala","sequence":"additional","affiliation":[{"name":"3Fondazione Gruppo Italiano Malattie EMatologiche dell'Adulto, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Nanni","sequence":"additional","affiliation":[{"name":"20Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice Anna","family":"Zannetti","sequence":"additional","affiliation":[{"name":"10Azienda Unit\u00e0 Sanitaria Locale della Romagna, Ospedale Santa Maria delle Croci, Ravenna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-969X","authenticated-orcid":false,"given":"Giorgia","family":"Simonetti","sequence":"additional","affiliation":[{"name":"21Biosciences Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Romagnolo per lo Studio dei Tumori \"Dino Amadori,\" Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-9189","authenticated-orcid":false,"given":"Maria Teresa","family":"Bochicchio","sequence":"additional","affiliation":[{"name":"21Biosciences Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Romagnolo per lo Studio dei Tumori \"Dino Amadori,\" Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-3514","authenticated-orcid":false,"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"15Allogeneic Transplant and Cell Therapies Unit, Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Azienda Ospedaliera-Universitari Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto M.","family":"Lemoli","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Clinic of Hematology, University of Genoa, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-0553","authenticated-orcid":false,"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[{"name":"22Dipartimento di Biomedicina e Prevenzione, Universit\u00e0 Tor Vergata, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1278-604X","authenticated-orcid":false,"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[{"name":"3Fondazione Gruppo Italiano Malattie EMatologiche dell'Adulto, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Fazi","sequence":"additional","affiliation":[{"name":"3Fondazione Gruppo Italiano Malattie EMatologiche dell'Adulto, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"5Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Bologna, Italy"},{"name":"20Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"12","key":"2025052708521013400_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025052708521013400_bib2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"issue":"27","key":"2025052708521013400_bib3","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025052708521013400_bib4","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3324\/haematol.12004","article-title":"Acute Leukemia Working Party of the GIMEMA group. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia","volume":"93","author":"Lo-Coco","year":"2008","journal-title":"Haematologica"},{"issue":"29","key":"2025052708521013400_bib5","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2012.42.2907","article-title":"Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm\u2013combined prospective analysis by the German AML Intergroup","volume":"30","author":"B\u00fcchner","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025052708521013400_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00277-023-05087-8","article-title":"Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study","volume":"102","author":"Niederwieser","year":"2023","journal-title":"Ann Hematol"},{"issue":"8","key":"2025052708521013400_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24391","article-title":"High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: a critical review of a 10-year, single-center experience in younger, non M3 AML patients","volume":"91","author":"Guolo","year":"2016","journal-title":"Am J Hematol"},{"issue":"3-4","key":"2025052708521013400_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/10428190109057932","article-title":"Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia","volume":"40","author":"Russo","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2025052708521013400_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.15106","article-title":"Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information","volume":"184","author":"Minetto","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"2025052708521013400_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"2025052708521013400_bib11","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"2025052708521013400_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-021-00555-8","article-title":"6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. [published correction appears in Blood Cancer J. 2021;11(10):171]","volume":"11","author":"Wei","year":"2021","journal-title":"Blood Cancer J"},{"issue":"33","key":"2025052708521013400_bib13","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025052708521013400_bib14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"30","key":"2025052708521013400_bib15","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"issue":"30","key":"2025052708521013400_bib16","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.20.01788","article-title":"BCL-2 inhibitor and conventional chemotherapy combinations for acute myeloid leukemia: shifting from the unfit to the fit patient with AML","volume":"38","author":"Ossenkoppele","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025052708521013400_bib17","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"25","key":"2025052708521013400_bib18","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025052708521013400_bib19","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"2025052708521013400_bib20","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"issue":"19","key":"2025052708521013400_bib21","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2025052708521013400_bib22","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025052708521013400_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2025052708521013400_bib24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2025052708521013400_bib25","unstructured":"US Department of Health and Human Services\n          . Common terminology criteria for adverse events (CTCAE) version 5.0. Updated 27 November 2017. Accessed 15 June 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"8","key":"2025052708521013400_bib26","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/bloodadvances.2021005717","article-title":"ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol","volume":"6","author":"Buccisano","year":"2022","journal-title":"Blood Adv"},{"key":"2025052708521013400_bib27","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"2","key":"2025052708521013400_bib28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"9","key":"2025052708521013400_bib29","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00277-021-04565-1","article-title":"Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. [published correction appears in Ann Hematol. 2021;100(11):2877-2878]","volume":"100","author":"Heinicke","year":"2021","journal-title":"Ann Hematol"},{"issue":"20","key":"2025052708521013400_bib30","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system","volume":"29","author":"R\u00f6llig","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025052708521013400_bib31","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.21.01548","article-title":"Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses","volume":"40","author":"Norsworthy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025052708521013400_bib32","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"26","key":"2025052708521013400_bib33","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025052708521013400_bib34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2025052708521013400_bib35","doi-asserted-by":"crossref","first-page":"107368","DOI":"10.1016\/j.leukres.2023.107368","article-title":"Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed\/refractory patients with AML-a systematic review","volume":"133","author":"Sherban","year":"2023","journal-title":"Leuk Res"},{"issue":"8","key":"2025052708521013400_bib36","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00277-022-04883-y","article-title":"Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis","volume":"101","author":"Wolach","year":"2022","journal-title":"Ann Hematol"},{"issue":"11","key":"2025052708521013400_bib37","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1084\/jem.20030031","article-title":"Marrow stem cells shift gene expression and engraftment phenotype with cell cycle transit","volume":"197","author":"Lambert","year":"2003","journal-title":"J Exp Med"},{"issue":"6464","key":"2025052708521013400_bib38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"issue":"12","key":"2025052708521013400_bib39","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"2025052708521013400_bib40","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2025052708521013400_bib41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ajcp\/aqab172","article-title":"Distinct mutation landscapes between acute myeloid leukemia with myelodysplasia-related changes and de novo acute myeloid leukemia","volume":"157","author":"Gao","year":"2022","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"2025052708521013400_bib42","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3324\/haematol.2018.215269","article-title":"Clonal hematopoiesis and risk of acute myeloid leukemia","volume":"104","author":"Young","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"2025052708521013400_bib43","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2025052708521013400_bib44","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/hon.2646","article-title":"Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis","volume":"37","author":"Agarwal","year":"2019","journal-title":"Hematol Oncol"},{"issue":"16","key":"2025052708521013400_bib45","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2025052708521013400_bib46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-020-00361-8","article-title":"CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program","volume":"10","author":"Guolo","year":"2020","journal-title":"Blood Cancer J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2542\/2375286\/blooda_adv-2024-014901-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2542\/2375286\/blooda_adv-2024-014901-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:52:25Z","timestamp":1748350345000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2542\/535910\/Safety-run-in-and-part-1-of-GIMEMA-AML1718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014901","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,27]]},"published":{"date-parts":[[2025,5,20]]}}}